NCT00358501View on ClinicalTrials.gov

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

March 31, 2015

Conditions
Severe Hepatic Veno-Occlusive Disease
Interventions
DRUG

Defibrotide

Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.

Trial Locations (25)

Unknown

Duarte

Palo Alto

Denver

Atlanta

Chicago

Maywood

Indianapolis

Baltimore

Boston

Ann Arbor

Minneapolis

Rochester

St Louis

Omaha

Hackensack

New York

Durham

Columbus

Portland

Philadelphia

Houston

Seattle

Vancouver

Toronto

Montreal

Sponsors
All Listed Sponsors
collaborator

FDA Office of Orphan Products Development

FED

lead

Jazz Pharmaceuticals

INDUSTRY